Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-30
2006-05-30
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S378000, C530S300000, C530S350000, C424S094100, C424S094600, C424S009100, C424S178100, C435S195000
Reexamination Certificate
active
07053042
ABSTRACT:
The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
REFERENCES:
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5603933 (1997-02-01), Dwyer, IV et al.
patent: 5618790 (1997-04-01), Kennedy et al.
patent: 5741821 (1998-04-01), Roufogalis et al.
patent: 5866679 (1999-02-01), DeFeo-Jones et al.
patent: 5905089 (1999-05-01), Hwang et al.
patent: 5955431 (1999-09-01), Stevens et al.
patent: 6545131 (2003-04-01), Isaacs et al.
patent: 3-15886 (1991-01-01), None
patent: WO 97/28272 (1997-08-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 99/40930 (1999-08-01), None
Treiman et al., “A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+- ATPases”, TiPS, Apr. 1998, vol. 19, pp 131-135.
Anderen et al., “Ca2+-ATPase Inhibitory Activity Of a Locked Analogue of Thapsigargin”,Bioorganic&Medicinal Chemistry Letters,vol. 4, No. 5, pp 657-660, 1994.
Nielsen et al., “Structure-Activity Relationships of Analogues of Thapsigargin Modified at 0-11 and 0-12”,J. Med. Chem.,1995, vol. 38, pp 272-276.
Bourgeois et al., “Serpin-derived Peptide Substrates . . . Kallikreins hK1 and hK2”,The Journal of Biological Chemistry,vol. 272, No. 47, Issue of Nov. 21, pp. 29590-29595, 1997.
Denmeade et al., “Specific and Efficient Peptide . . . of Prostate-specific Antigen”,Cancer Research,vol. 57, pp. 4924-4930, Nov. 1,1997.
Coombs et al., Substrate specificity of prostate-specific antigen (PSA),Chemistry&Biology,vol. 5, No. 9, Sep. 1998, pp 475-488.
Brillard-Bourdet et al., “Substrate specificity . . . extended interaction site”,BBA,vol. 1246, No. 1, Jan. 5, 1995, pp. 47-52.
Devi, “Consensus sequence . . . peptide precursors . . . sites”,FEBS LETTERS,vol. 280, No. 2, Mar. 25, 1991, pp 189-194.
Nakayama et al., “Consensus Sequence for Precursor Processing at Mono-arginyl Sites”,The Journal of Biological Chemistry, vol. 267, No. 23, Issue of Aug. 15, pp. 16335-16340, 1992.
Dube, “La Kallicreine HK2 Peut-Elle Favoriser La Progression Des Tumeurs Cancereuses De La Prostate”, Science and Medicine, 14(1):111-113 (1998).
Bougeois et al., Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikrein hk1 and hk2, Journal of Biological Chemistry, 272(47) :29590-29595 (1997).
Lovgren et al., “Enzymatic action of human glandular kallikrein 2 (hK2) : Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors”, European Journal of Biochemistry, 262 (3) : 781-789 (1999).
Mikolajczyk et al., “Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors”, Prostate, 34 (1) :44-50 (1998).
Denmeade et al., “Enzymatic Activation of Prodrugs by Prostate-Specific Antigen: Targeted Thereapy for Metastatic Prostate Cancer” , Cancer Journal from Scientific American, 4, Suppl. 1:S15-S21 (1998).
Denmeade et al., “Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen”, Cancer Research, 58:2537-2540 (1994).
James et al., “Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Juclear 70K Ribonucleoprotein”, Scandinavian Journal of Immunology, 39 (6) :557-566 (1994).
Pimenta et al., “Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids”, Biochemical Journal, 339 (2) :473-479 (1999).
Denmeade Samuel R.
Isaacs John T.
Lilja Hans
Corless Peter F.
Denmeade Samuel
Edwards & Angell LLP
Isaacs John Tod
Lilja Hans
LandOfFree
Activation of peptide prodrugs by hK2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activation of peptide prodrugs by hK2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of peptide prodrugs by hK2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591275